Trial of bromelians (NexoBrid) in patients aged 4-55 years with deep-partial and full-thickness burns

Trial Profile

Trial of bromelians (NexoBrid) in patients aged 4-55 years with deep-partial and full-thickness burns

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Bromelains (Primary)
  • Indications Burns
  • Focus Registrational; Therapeutic Use
  • Sponsors MediWound
  • Most Recent Events

    • 20 Oct 2015 According to MediWound media release, bromelain topical (NexoBrid) has been authorized for marketing in Argentina by the Ministry of Health in Argentina.
    • 30 Mar 2015 New trial record
    • 23 Mar 2015 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top